Current and future treatment of SCD

Josh Wright, BMedSci (Hons), MBChB, FRCPath, MD, BSH President, discusses the current and future treatment landscape of sickle cell disease (SCD), drawing focus on novel gene therapies and therapeutic agents. Dr Wright first explains that while current treatment options such as hydroxycarbamide and transfusion are effective, they do not work for all patients and come with risk factors. Dr Wright then discusses some upcoming treatment options, including pyruvate kinase agonists and crizanlizumab, and the importance of further investigating their long-term effects and providing more options for sickle cell patients. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Be the first to comment